China In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due diligence. Servier’s Asia BD Head Cynthia Xin Wang explains how this shift reflects changing market dynamics and the growing importance…
China Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, and Takeda made it clear that Big Pharma’s interest in the country has…
India Regular contributor Brendan Shaw gives his informed take on how best international stakeholders can engage with India’s attempts to transform into a global pharma innovation powerhouse, Our greatest ability as humans is not to change the world, but to change ourselves Mahatma Gandhi The secret to success in India…
Greece EY Greece’s George Mitropoulos outlines some of the key challenges and opportunities for both local manufacturers and multinational innovators in Greece, how EY is uniquely positioned to assist them, and the fundamentals that give him cause for optimism for both the Greek economy and its healthcare sector. We believe…
USA David H. Crean, Managing Partner for Cardiff Advisory, discusses the economic impact of the signing and implementation of the Inflation Reduction Act (IRA) on the biopharmaceutical industry and innovation. America’s biopharmaceutical research companies are researching and developing new medicines to meet unmet needs and continuing research and development even…
USA Monica Weldon draws on her own experience as a rare disease patient advocacy group CEO to outline how such groups can work collaboratively with other stakeholders in drug development to better target funding and create a more patient-centric drug development process that ultimately gets better drugs to rare disease patients…
Korea KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19 pandemic, and how Korean infrastructure and expertise is helping train up scientists from low- and middle-income countries. My hope…
Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…
Egypt As of today, the Evergreen boat that blocked global shipping when it got stuck in the Suez Canal has still not been allowed to leave Egypt. The infamous episode illustrated the complex situation that has affected global economies during the pandemic. But, for Egypt, the liberation of the canal symbolized…
USA Writing in the May edition of DIA’s Global Forum magazine, Erica Lyons, Sarrit Kovacs, Matthew Kowalik, and Jessica Lee from the Division of Gastroenterology, Office of New Drugs, CDER at the US FDA look at how patient input is increasingly being utilised in new drug development, its importance in assessing…
Singapore Changi Airport Group’s Ching Kiat LIM reflects on a challenging 2020 for the airline industry, Changi’s longstanding excellence in pharmaceutical distribution, and how COVID-19 has pushed a greater embrace of cutting-edge digital tools. We see ourselves as the conductor of an orchestra, where all the instruments must play in…
Brazil The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached USD 21.8 billion, with almost two thirds coming from retail. The overall LatAm pharma market grew 6 percent in average…
See our Cookie Privacy Policy Here
